The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HAE | -29.94% | -51.99% | -13.64% | +765% |
| S&P | +16.23% | +94.45% | +14.22% | +1,693% |
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
The company broadly meets expectations for its Q2 2022 but trims its full-year guidance.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $321.39M | -4.4% |
| Gross Profit | $180.47M | 8.2% |
| Gross Margin | 56.15% | 6.5% |
| Market Cap | $3.58B | -15.0% |
| Market Cap / Employee | $1.19M | 0.0% |
| Employees | 3K | -17.3% |
| Net Income | $34.03M | -11.3% |
| EBITDA | $83.90M | 14.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $292.90M | -15.0% |
| Accounts Receivable | $200.75M | -0.4% |
| Inventory | 360.5 | -3.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $920.83M | -24.4% |
| Short Term Debt | $303.95M | 5849.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.53% | 1.4% |
| Return On Invested Capital | 6.34% | 0.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $13.64M | 141.2% |
| Operating Free Cash Flow | $17.40M | 163.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 33.14 | 30.53 | 19.05 | 22.52 | -39.22% |
| Price to Book | 4.54 | 4.48 | 3.52 | 4.38 | 0.13% |
| Price to Sales | 3.00 | 2.86 | 2.30 | 2.65 | -17.10% |
| Price to Tangible Book Value | -20.26 | -17.47 | -19.46 | -15.04 | -95.98% |
| Price to Free Cash Flow TTM | 107.96 | 40.95 | 21.95 | 18.86 | -67.74% |
| Enterprise Value to EBITDA | 58.51 | 52.77 | 51.50 | 53.64 | -23.35% |
| Free Cash Flow Yield | 0.9% | 2.4% | 4.6% | 5.3% | 209.97% |
| Return on Equity | 14.0% | 14.1% | 18.8% | 18.3% | 40.76% |
| Total Debt | $1.22B | $1.22B | $1.28B | $1.22B | 0.10% |
HAE earnings call for the period ending October 2, 2021.
HAE earnings call for the period ending July 3, 2021.
HAE earnings call for the period ending April 3, 2021.
HAE earnings call for the period ending February 26, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
